James B. Tananbaum has bought stock on 7 days since Dec 2020
Director and 10% owner at Alumis Inc., and 1 other company
SEC CIK 0001581754 · Filings on SEC.gov ↗
James B. Tananbaum's record
3 months after each buy, from the first price a copier could get.
6 buys since 2020 with 3 months of prices.
Companies
Every filing
7 filings since Dec 2020, newest first
Alumis Inc.
Director and 10% owner
Alumis Inc.
Director and 10% owner
Alumis Inc.
Director and 10% owner
Alumis Inc.
Director and 10% owner
Alumis Inc.
Director and 10% owner
Kinnate Biopharma Inc.
Director and 10% owner
Kinnate Biopharma Inc.
Director and 10% owner
About James B. Tananbaum
James B. Tananbaum, M.D., M.B.A. is an independent Class II Director at Alumis Inc. (ALMS), serving since January 2021 and as a member of the Compensation Committee.( Age 62, he holds significant ownership (~15.8%) through Foresite Capital-affiliated funds, reflecting his recent insider trading activity as Director, 10%.( Tananbaum is the founder, President, and CEO of Foresite Capital Management, a U.S.-focused healthcare investment firm established in 2011 with ~$3.5B in assets under management, and co-founder of Foresite Labs.(
Tananbaum's career highlights include co-founding GelTex Pharmaceuticals (1991, acquired by Sanofi-Genzyme for $1.6B), serving as founding CEO of Theravance, Inc. (1997, spun into Innoviva and Theravance Biopharma with combined market cap exceeding $4B), and co-founding/managing director roles at Prospect Venture Partners (2000–2010).( Earlier, he was a partner at Sierra Ventures and senior product manager at Merck.( He holds an M.D. and M.B.A. from Harvard, and B.S. in Applied Math and B.S.E.E. from Yale.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.